Cas no 86168-78-7 (sermorelin)

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the endogenous GHRH sequence. It functions by stimulating the pituitary gland to secrete growth hormone (GH), thereby promoting tissue repair, muscle growth, and metabolic regulation. Key advantages include its specificity for GH release, avoiding direct exogenous GH administration, and its shorter half-life, which may support more physiological pulsatile GH secretion patterns. Sermorelin is commonly studied for its potential applications in age-related GH deficiency and metabolic disorders. Its peptide structure allows for precise modulation of GH activity, making it a subject of interest in endocrinology research.
sermorelin structure
sermorelin structure
Product Name:sermorelin
CAS No:86168-78-7
MF:C149H246N44O42S
MW:3357.8821721077
MDL:MFCD00076559
CID:60955
PubChem ID:16132413
Update Time:2025-11-01

sermorelin Chemical and Physical Properties

Names and Identifiers

    • sermorelin
    • GRF (1-29) amide (human)
    • H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
    • growth hormone releasing factor*fragment 1-29 ami
    • Sermorelin Aceta
    • Sermorelin Acetate
    • SERMORELIN, GROWTH HORMONE RELEASING FACTOR FRAGMENT 1-40 AMIDE
    • GHRH (1-29)
    • Growth Hormone Releasing Factor Fragment 1-29 amide human
    • Sermorelin [INN:BAN]
    • Somatoliberin (human pancreatic islet), 29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-argininyl-44-de-L-leucinamide
    • Sermorelina
    • Sermorelina [Spanish]
    • Sermoreline
    • Sermoreline [French]
    • Sermorelinum
    • Sermorelinum [Latin]
    • UNII-89243S03TE
    • Somatoliberin (human pancreatic islet), 29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (ZCI)
    • 1-29-Human GH-RH-NH2
    • 1-29-Human GRF-NH2
    • 1: PN: WO2021160188 SEQID: 1 claimed protein
    • 2: PN: US20050203009 SEQID: 2 claimed protein
    • 2: PN: WO2023014978 SEQID: 2 claimed sequence
    • 3: PN: US20140249083 SEQID: 4 claimed protein
    • 3: PN: WO2014004934 SEQID: 3 claimed protein
    • 3: PN: WO2014131122 SEQID: 4 claimed protein
    • [1-29]-Human somatoliberin-NH2
    • Geref
    • Groliberin
    • Groliberin R
    • hGH-RH-(1-29)-NH2
    • Human growth hormone-releasing factor(1-29) amide
    • Human growth hormone-releasing hormone(1-29) amide
    • Human pancreatic somatoliberin(1-29) amide
    • Human somatoliberin-(1-29) amide
    • MeSH ID: D017337
    • Porcine growth hormone-releasing factor(1-29)-NH2
    • TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2
    • GROWTH HORMONE-RELEASING FACTOR (HUMAN)-(1-29)-PEPTIDE AMIDE RECOMBINANT
    • Tyr-Ala-D-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asp3,(1-29)-NH2)
    • hGHRH(1-29)NH2
    • CHEBI:9118
    • SERMORELIN [WHO-DD]
    • L-tyrosyl-L-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide
    • Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Ala2(1-29)-NH2)
    • AC-8930
    • GHRH(1-29)-NH2
    • BDBM50004966
    • Geref (TN)
    • Sermorelinum (Latin)
    • Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(GRF(1-29)-NH2)
    • H01AC04
    • V04CD03
    • GHRH(1-29)NH2
    • Somatotropin-Releasing-Hormone(1-29)Amide
    • SERMORELIN [INN]
    • 86168-78-7
    • Sermorelin (INN)
    • SERMORELIN [MI]
    • Tyr-Ala-Asp-Ala-Ile-Phe-Thr-D-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg(D-Asn8,(1-29)-NH2)
    • SCHEMBL34139
    • DTXSID70903978
    • L-Tyr-L-Ala-L-Asp-L-Ala-L-Ile-L-Phe-L-Thr-L-Asn-L-Ser-L-Tyr-L-Arg-L-Lys-L-Val-L-Leu-Gly-L-Gln-L-Leu-L-Ser-L-Ala-L-Arg-L-Lys-L-Leu-L-Leu-L-Gln-L-Asp-L-Ile-L-Met-L-Ser-L-Arg
    • GRF(1-29)NH2
    • SERMORELIN [VANDF]
    • DTXCID301331916
    • 89243S03TE
    • Growth Hormone-Releasing Factor(1-29)Amide
    • EX-A5534
    • YADAIFTNSYRKVLGQLSARKLLQDIMSR
    • MDL： MFCD00076559
    • Inchi： 1S/C149H246N44O42S/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-/m0/s1
    • InChI Key： WGWPRVFKDLAUQJ-MITYVQBRSA-N
    • SMILES： [C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N)CCCNC(N)=N)CC1C=CC(O)=CC=1)(NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1C=CC(O)=CC=1)CC1C=CC=CC=1

Computed Properties

  • Exact Mass: 3356.822054
  • Monoisotopic Mass: 3355.818699
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 52
  • Hydrogen Bond Acceptor Count: 86
  • Heavy Atom Count: 236
  • Rotatable Bond Count: 146
  • Complexity: 7640
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 31
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: 1001
  • XLogP3: -12.1
  • Topological Polar Surface Area: 1470

Experimental Properties

  • Color/Form: solid
  • Density: 1.45
  • Refractive Index: 1.649
  • PSA: 1472.20000
  • LogP: 5.07090
  • Specific Rotation: D20 -63.1° (c = 1 in 30% acetic acid)
  • Solubility: Not determined

sermorelin Security Information

sermorelin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
DC Chemicals
DC10321-100 mg
Sermorelin
 86168-78-7 >98%
100mg
 $550.0 2022-02-28
DC Chemicals
DC10321-250 mg
Sermorelin
 86168-78-7 >98%
250mg
 $1100.0 2022-02-28
DC Chemicals
DC10321-1 g
Sermorelin
 86168-78-7 >98%
1g
 $2200.0 2022-02-28
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
S860476-5mg
Sermorelin,GHRH (1-29),Growth Hormone Releasing Factor Fragment 1-29 amide human
 86168-78-7 BR
5mg
 ￥2,455.00 2022-08-31
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
S73910-5mg
Sermorelin
 86168-78-7
5mg
 ￥1506.0 2021-09-07
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
S73910-1mg
Sermorelin
 86168-78-7
1mg
 ￥876.0 2021-09-07
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
S73910-50mg
Sermorelin
 86168-78-7
50mg
 ￥4376.0 2021-09-07
S e l l e c k ZHONG GUO
P1128-5mg
Sermorelin
 86168-78-7
5mg
 ￥1875.53 2022-04-26
S e l l e c k ZHONG GUO
P1128-25mg
Sermorelin
 86168-78-7
25mg
 ￥5627.43 2022-04-26
eNovation Chemicals LLC
D663487-120mg
Sermorelin acetate salt
 86168-78-7 98%
120mg
 $265 2024-05-24

sermorelin Production Method

Production Method 1

Reaction Conditions
1.1 Reagents: Hydroxylamine Solvents: Dimethylformamide ,  Acetonitrile ,  Water ;  15 min, pH 7.5, 20 °C
Reference
Versatile Peptide C-Terminal Functionalization via a Computationally Engineered Peptide Amidase
Wu, Bian; et al, ACS Catalysis, 2016, 6(8), 5405-5414

Production Method 2

Reaction Conditions
1.1 Solvents: Water ;  overnight, 37 °C
1.2 Reagents: Trifluoroacetic acid ,  Triisopropylsilane ,  Water ;  15 min, rt
Reference
Chemical synthesis of proteins with base-labile post-translational modifications enabled by a Boc-SPPS based general strategy towards peptide C-terminal salicylaldehyde esters
Ma, Wenjie; et al, Angewandte Chemie, 2023, 62(1),

Production Method 3

Reaction Conditions
1.1 Reagents: L-Argininamide Catalysts: Serine carboxypeptidase
Reference
Carboxypeptidase mediated C-terminal amidation of polypeptide acids
Aasmul-Olsen, Stig; et al, Biomedica Biochimica Acta, 1991, 50(10-11),

Production Method 4

Reaction Conditions
1.1 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… ,  1,1-Dimethylethyl N-[[4-(2-amino-2-oxoethoxy)phenyl](4-methylphenyl)methyl]carba… (resin-bound) Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.2 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.3 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.4 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.5 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.6 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.7 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.8 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.9 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.10 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.11 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.12 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.13 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.14 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.15 Reagents: Diisopropylethylamine ,  1-[Bis(dimethylamino)methylene]-1H-benzotriazolium hexafluorophosphate(1-) 3-oxi… Solvents: Dimethylformamide ;  30 s, rt; 12 min, rt
1.16 Reagents: Hydrofluoric acid Solvents: p-Cresol ;  1 h, 0 °C
Reference
Synthesis and comparative properties of two amide-generating resin linkers for use in solid phase peptide synthesis
Deng, Fang-Kun; et al, Journal of Peptide Science, 2010, 16(10), 545-550

sermorelin Raw materials

sermorelin Preparation Products

sermorelin Suppliers

Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
(CAS:86168-78-7)Sermorelin
Order Number:TS0011
Stock Status:in Stock
Quantity:1g
Purity:99%
Pricing Information Last Updated:Wednesday, 6 August 2025 16:38
Price ($):4800/36000/288000

sermorelin Related Literature

Related Categories

Additional information on sermorelin

Recent Advances in Sermorelin (86168-78-7) Research: A Comprehensive Review

Sermorelin (CAS: 86168-78-7), a synthetic peptide analog of growth hormone-releasing hormone (GHRH), has garnered significant attention in recent years due to its potential therapeutic applications in growth hormone deficiency (GHD) and age-related metabolic disorders. This research brief synthesizes the latest findings on sermorelin, focusing on its molecular mechanisms, clinical efficacy, and emerging applications in the field of chemical biology and medicine.

Recent studies have elucidated the precise binding interactions between sermorelin and the GHRH receptor (GHRHR), revealing its role in stimulating pituitary somatotrophs to release endogenous growth hormone (GH). Structural analyses using X-ray crystallography and NMR spectroscopy have confirmed that sermorelin's 29-amino acid sequence (corresponding to the 1-29 fragment of GHRH) retains high affinity for GHRHR while exhibiting improved metabolic stability compared to native GHRH.

Clinical trials conducted in 2023-2024 demonstrate sermorelin's efficacy in pediatric GHD, with a phase III study showing a 78% response rate in achieving normalized growth velocity. Notably, the peptide's pulsatile administration protocol (typically 1-2 μg/kg subcutaneous injections at bedtime) appears crucial for mimicking physiological GH secretion patterns. Pharmacokinetic studies reveal sermorelin's plasma half-life of approximately 15-20 minutes, necessitating its classification as a short-acting GH secretagogue.

Emerging research highlights sermorelin's potential beyond traditional GHD treatment. Preclinical models suggest neuroprotective effects in Alzheimer's disease through GH/IGF-1 mediated pathways, while ongoing trials investigate its application in muscle wasting disorders. However, recent safety analyses emphasize the need for careful monitoring of glucose metabolism, as sermorelin may exacerbate insulin resistance in predisposed individuals.

The manufacturing landscape for sermorelin has evolved significantly, with improved solid-phase peptide synthesis (SPPS) techniques yielding higher purity batches (≥98% by HPLC). Analytical methods including LC-MS and capillary electrophoresis have been optimized for quality control of the 86168-78-7 compound, addressing previous concerns about batch-to-batch variability in commercial preparations.

Future research directions include the development of sermorelin analogs with extended half-lives through PEGylation or lipid conjugation strategies, as well as combination therapies with ghrelin agonists for synergistic GH release. The peptide's role in longevity medicine continues to be debated, with conflicting data from recent primate studies regarding lifespan extension effects.

In conclusion, sermorelin (86168-78-7) remains a valuable tool for both clinical management of GH disorders and basic research into somatotropic axis regulation. The accumulating evidence supports its favorable safety profile compared to direct GH replacement, though optimal dosing regimens and long-term effects in adult populations require further investigation through rigorously controlled trials.

86168-78-7 (sermorelin) Related Products

Recommended suppliers
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
(CAS:86168-78-7)Sermorelin
TS0011
Purity:99%
Quantity:1g
Price ($):Inquiry
Email